Correlation between inflammation state and successful medical cardioversion using bepridil for refractory atrial fibrillation

Journal of Cardiology

Volumn 62, Issue 2, 2013, Pages 117-120

  Nishino, Masami ^a   Mori, Naoki ^a   Nakamura, Daisuke ^a   Lee, Yasuharu ^a   Yoshimura, Takahiro ^a   Taniike, Masayuki ^a   Makino, Nobuhiko ^a   Kato, Hiroyasu ^a   Egami, Yasuyuki ^a   Shutta, Ryu ^a   Tanouchi, Jun ^a   Yamada, Yoshio ^a  

^a OSAKA ROSAI HOSPITAL   (Japan)

Author keywords

Atrial fibrillation; Bepridil; Cardioversion; Inflammation

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CIBENZOLINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PILSICAINIDE; PROPAFENONE; WARFARIN;

ADULT; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HEART LEFT ATRIUM DIMENSION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HUMAN; HYPERTENSION; INFLAMMATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; QT PROLONGATION; RECURRENT DISEASE; SINUS BRADYCARDIA; SINUS RHYTHM; TREATMENT FAILURE;

ATRIAL FIBRILLATION; BEPRIDIL; CARDIOVERSION; INFLAMMATION;

AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BEPRIDIL; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ELECTRIC COUNTERSHOCK; FEMALE; HEART ATRIA; HEART RATE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; SINOATRIAL NODE; STROKE VOLUME; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84880136237     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2013.03.003     Document Type: Article

References (25)

1. Aviles R.J., Martin D.O., Apperson-Hansen C., Houghtaling P.L., Rautaharju P., Kronmal R.A., Tracy R.P., Van Wagoner D.R., Psaty B.M., Lauer M.S., Chung M.K. Inflammation as a risk factor for atrial fibrillation. Circulation 2003, 108:3006-3010.
2. Psychari S.N., Apostolou T.S., Sinos L., Hamodraka E., Liakos G., Kremastinos D.T. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol 2005, 95:764-767.
3. Dernellis J., Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 2004, 25:1100-1107.
4. Malouf J.F., Kanagala R., Al Atawi F.O., Rosales A.G., Davison D.E., Murali N.S., Tsang T.S., Chandrasekaran K., Ammash N.M., Friedman P.A., Somers V.K. High sensitivity C-reactive protein: a novel predictor for recurrence of atrial fibrillation after successful cardioversion. J Am Coll Cardiol 2005, 46:1284-1287.
5. Wazni O., Martin D.O., Marrouche N.F., Shaaraoui M., Chung M.K., Almahameed S., Schweikert R.A., Saliba W.I., Natale A. C reactive protein concentration and recurrence of atrial fibrillation after electrical cardioversion. Heart 2005, 91:1303-1305.
6. Fujiki A., Tsuneda T., Sugao M., Mizumaki K., Inoue H. Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. Am J Cardiol 2003, 92:472-475.
7. Fujiki A., Tsuneda T., Sakabe M., Nakagawa K., Mizumaki K., Hirai T., Inoue H. Maintenance of sinus rhythm and recovery of atrial mechanical function after cardioversion with bepridil or in combination with aprindine in long-lasting persistent atrial fibrillation. Circ J 2004, 68:834-839.
8. Fujiki A., Sakamoto T., Nishida K., Mizumaki K., Inoue H. Relation of interleukin-6 and C-reactive protein levels to sinus maintenance after pharmacological cardioversion in persistent atrial fibrillation. J Cardiovasc Pharmacol 2007, 50:264-266.
9. Egami Y., Nishino M., Taniike M., Makino N., Kato H., Shutta R., Tanouchi J., Yamada Y. Efficacy and safety of bepridil for patients with persistent atrial fibrillation after failed electrical cardioversion. J Arrhythmia 2011, 27:131-136.
10. Fuster V., Ryden L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., Halperin J.L., Kay G.N., Le Huezey J.Y., Lowe J.E., Olsson S.B., Prystowsky E.N., Tamargo J.L., Wann L.S. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol 2011, 57:e101-e198.
11. Silverman D.I., Manning W.J. Role of echocardiography in patients undergoing elective cardioversion of atrial fibrillation. Circulation 1998, 98:479-486.
12. Korantzopoulos P., Kolettis T.M., Goudevenos J.A., Siogas K. Errors and pitfalls in the non-invasive management of atrial fibrillation. Int J Cardiol 2005, 104:125-130.
13. Van Gelder I.C., Hemels M.E. The progressive nature of atrial fibrillation: a rationale for early restoration and maintenance of sinus rhythm. Europace 2006, 8:943-949.
14. Ogawa S., Yamashita T., Yamazaki T., Aizawa Y., Atarashi H., Inoue H., Ohe T., Ohtsu H., Okumura K., Katoh T., Kamakura S., Kumagai K., Kurachi Y., Kodama I., Koretsune Y., et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM study. Circ J 2009, 73:242-248.
15. Sponga S., Leoni L., Buja G., Nalli C., Voisine P., Gerosa G. Role of an aggressive rhythm control strategy on sinus rhythm maintenance following intra-operative radiofrequency ablation of atrial fibrillation in patients undergoing surgical correction of valvular disease. J Cardiol 2012, 60:316-320.
16. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002, 415:219-226.
17. Nishino M., Hoshida S., Tanouchi J., Ito T., Kato J., Iwai K., Tanahashi H., Hori M., Yamada Y., Kamada T. Time to recover from atrial hormonal, mechanical, and electrical dysfunction after successful electrical cardioversion of persistent atrial fibrillation. Am J Cardiol 2000, 85:1451-1454.
18. Issac T.T., Dokainish H., Lakkis N.M. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 2007, 50:2021-2028.
19. Bruins P., te Velthuis H., Yazdanbakhsh A.P., Jansen P.G., van Hardevelt F.W., de Beaumont E.M., Wildevuur C.R., Eijsman L., Trouwborst A., Hack C.E. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 1997, 96:3542-3548.
20. Chung M.K., Martin D.O., Sprecher D., Wazni O., Kanderian A., Carnes C.A., Bauer J.A., Tchou P.J., Niebauer M.J., Natale A., Van Wagoner D.R. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001, 104:2886-2891.
21. Liu T., Li G., Li L., Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 2007, 49:1642-1648.
22. Loricchio M.L., Cianfrocca C., Pasceri V., Bianconi L., Auriti A., Calo L., Lamberti F., Castro A., Pandozi C., Palamara A., Santini M. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 2007, 99:1421-1424.
23. Liu T., Li L., Korantzopoulos P., Goudevenos J.A., Li G. Meta-analysis of association between C-reactive protein and immediate success of electrical cardioversion in persistent atrial fibrillation. Am J Cardiol 2008, 101:1749-1752.
24. Makita Y., Nakano Y., Oda N., Suenari K., Sairaku A., Kajihara K., Tokuyama T., Motoda C., Fujiwara M., Yamamoto H., Awai K., Kihara Y. Use of preprocedural multidetector computed tomography to decrease atrial fibrillation recurrence following extensive encircling circumferential pulmonary vein isolation. J Cardiol 2012, 60:236-241.
25. Yamashita T., Ogawa S., Sato T., Aizawa Y., Atarashi H., Fujiki A., Inoue H., Ito M., Katoh T., Kobayashi Y., Koretsune Y., Kumagai K., Niwano S., Okazaki O., Okumura K., et al. Dose-response effects of bepridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: a multicenter, randomized, placebo-controlled, double-blind study (J-BAF study). Circ J 2009, 73:1020-1027.